Gyre Therapeutics – Focused on organ fibrosis and inflammatory disease
Catalyst Biosciences was a South San Francisco-based biopharmaceutical company focused on developing protein therapeutics for rare bleeding disorders including hemophilia. In 2023, GC Biopharma acquired Catalyst's rare hematology pipeline assets while Catalyst completed a reverse merger with GNI Group's Beijing Continent Pharmaceuticals, pivoting to fibrosis treatments.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountOct 2023
Oct 2011
Jan 2011
Jun 2010
Dec 2008
Feb 2006
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
